Research | Alzheimer's Prevention Registry

You are here


The Alzheimer’s Prevention Registry: A Large Internet-Based Participant Recruitment Registry to Accelerate Referrals to Alzheimer’s- Focused Studies

Recruitment for Alzheimer’s disease (AD) focused studies, particularly prevention studies, is challenging due to the public’s lack of awareness about study opportunities coupled with studies’ inclusion and exclusion criteria, resulting in a high screen fail rate. 

What are clinical trials and how do they work?

New drugs and medical devices are tested for safety and effectiveness in several phases of clinical trials. But how exactly does a clinical trial work? And what is the difference between Phase I and Phase II? This month we explore the inner workings of clinical trials and their role in testing new medical treatments. 

Alzheimer’s Prevention Registry wraps up 2021 and looks to 2022 for new study opportunities

Thank you for your continued support of our mission to end Alzheimer’s disease before losing another generation. As 2021 comes to a close, we are excited about the many new opportunities we foresee next year to participate in groundbreaking prevention research.

Alzheimer’s Disease Awareness Month shines spotlight other dementias

Alzheimer’s disease makes up 60 to 80 percent of all dementias. But what else can cause memory and thinking problems? Learn more about other causes of dementia along with their varied symptoms.

Digital devices and artificial intelligence partner to measure early brain changes

Smartphones and smartwatches already measure our heart rate, sleep patterns and oxygen levels. These and other so-called digital biomarkers coupled with artificial intelligence could one day soon identify early memory and thinking changes to help us optimize our brain health.

Study explores whether computerized brain training can prevent dementia

A new, NIH-funded, multi-site study is exploring whether computerized brain training can prevent dementia. Preventing Alzheimer’s with Cognitive Training (PACT) will examine whether a specific type of computerized training can reduce the risk of dementia such as Alzheimer’s disease for adults over 65.  

New study uses tailored dosing approach that aims to help prevent Alzheimer’s

A new Alzheimer’s clinical trial is recruiting people as young as 55 to participate in a study of an anti-amyloid investigational therapy. The study is groundbreaking because the study medication doses are tailored based on each participant’s level of brain amyloid. Read more about how the AHEAD Study aims to get ahead of Alzheimer’s before symptoms appear. 

Improving your sleep and other lifestyle factors are keys to better brain health

Sleep is your body’s way of restoring vital organs including the brain. When sleep is elusive over long periods of time, research shows it can increase the risk of dementia and cognitive decline. You can reduce your risk by improving your sleep habits and addressing other lifestyle factors such as physical activity, diet, social engagement and smoking cessation. Read more about how to improve these aspects of your lifestyle.

First treatment in two decades approved for Alzheimer’s

The FDA approved the first new treatment for Alzheimer’s disease in almost two decades on June 7. Aducanumab is also the first approved drug to change the course of the disease by removing brain plaques, a signature of Alzheimer’s. But mixed results on its ability to slow the decline of memory and thinking skills caused some researchers to question the effectiveness of the novel treatment.

Discrimination and bias found in dementia care

The Alzheimer’s Association surveyed Black, Hispanic, Asian and Native Americans about their access to Alzheimer’s and dementia care. The results, which are reported in the 2021 Facts and Figures Report, show discrimination is a barrier to care for many minority groups. The report shares statistics from the survey and recommendations to combat discrimination in dementia care.